GSK plc
HealthcareNYSE:GSK · New York Stock Exchange
+$0.31 today
Vol 2.39M · Avg 4.07M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $5.6B +89.5% | $3.0B -51.8% | $6.1B +11.5% | $5.5B +56.3% | $3.5B | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $3.7B +44.9% | $2.6B -10.5% | $2.9B +7.8% | $2.6B +24.6% | $2.1B | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 +100.0% | -$1.1B -11.3% | -$965.7M | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $344.0M | $0 | $0 -100.0% | $343.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$608.4M -129.1% | $2.1B +296.4% | -$1.1B +36.4% | -$1.7B -220.6% | $1.4B | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 -100.0% | $340.0M +142.1% | -$806.7M -6.3% | -$758.8M +34.7% | -$1.2B | $592.6M | $1.3B | $626.2M |
| Inventory | $0 +100.0% | -$294.0M +44.2% | -$527.1M -59.1% | -$331.3M -749.7% | $51.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $0 | $0 +100.0% | -$18.6M -103.1% | $608.5M | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$608.4M -129.8% | $2.0B +608.8% | $288.4M +124.2% | -$1.2B -147.7% | $2.5B | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$1.5B -11.0% | -$1.4B -231.3% | $1.1B -60.4% | $2.7B +355.4% | $584.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $7.1B +9.0% | $6.6B -16.9% | $7.9B -3.3% | $8.2B +2.6% | $8.0B | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.3B +55.8% | -$3.0B -82.6% | -$1.6B -16.0% | -$1.4B +47.0% | -$2.7B | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$4.4B -419.3% | $1.4B +179.5% | -$1.7B +54.6% | -$3.8B -2148.1% | $185.0M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$90.0M | $0 +100.0% | -$152.9M +13.8% | -$177.4M | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $195.6M +831.5% | $21.0M -99.1% | $2.4B +704.4% | $294.4M +1535.5% | $18.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $1.5B +219.7% | -$1.2B -8272.1% | $14.9M +100.3% | -$4.4B -329.9% | -$1.0B | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$5.7B -365.6% | -$1.2B +48.9% | -$2.4B +77.9% | -$10.9B -512.4% | -$1.8B | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $1.5B +226.3% | -$1.2B +60.4% | -$2.9B +48.3% | -$5.7B -184.2% | -$2.0B | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $14.7M -26.6% | $20.0M +60.9% | $12.4M -59.6% | $30.8M +46.6% | $21.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | -$2.5B -2.6% | -$2.4B +12.5% | -$2.8B +34.6% | -$4.3B -6.8% | -$4.0B | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$573.2M +49.5% | -$1.1B -232.3% | -$341.8M -102.9% | $12.0B +845.1% | -$1.6B | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$1.6B +66.3% | -$4.7B +22.1% | -$6.1B -396.3% | $2.0B +127.0% | -$7.6B | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$32.9M +39.0% | -$54.0M +64.9% | -$153.8M +75.9% | -$638.0M -2099.9% | -$29.0M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$206.1M -137.8% | $545.0M +174.1% | -$735.6M +43.9% | -$1.3B +9.2% | -$1.4B | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $5.8B +63.1% | $3.6B -42.9% | $6.3B -7.3% | $6.8B +27.5% | $5.3B | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$129.95B
Bristol-Myers Squibb Company
NYSE:BMY
$116.55B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.69B
Sanofi
NASDAQ:SNY
$106.46B
McKesson Corporation
NYSE:MCK
$94.83B
Elevance Health Inc.
NYSE:ELV
$87.28B
HCA Healthcare, Inc.
NYSE:HCA
$85.76B
Cigna Corporation
NYSE:CI
$78.85B
Zoetis Inc.
NYSE:ZTS
$33.64B
Bristol-Myers Squibb Company Ce
CELG-RI
$250.97M
SEC Filings
Recent regulatory filings
No filings found.
Does GSK generate free cash flow?
GSK plc (GSK) generated $5.82B of free cash flow in fiscal 2025.
How much operating cash flow does GSK produce?
Operating cash flow was $7.14B, before capital expenditures of $1.32B.
Explore More
Continue the stock analysis
Jump to another research area for this company.